ArriVent BioPharma, Inc. Common Stock
AVBP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $762 | $627 | $895 |
| - Cash | $113 | $113 | $50 | $74 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $649 | $577 | $821 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$35 | -$31 | -$67 | -$24 |
| % Margin | – | – | – | – |
| Net Income | -$35 | -$31 | -$64 | -$21 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.83 | -0.9 | -1.9 | -0.61 |
| % Growth | 7.8% | 52.6% | -211.5% | – |
| Operating Cash Flow | -$36 | -$26 | -$68 | -$16 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$36 | -$26 | -$68 | -$16 |